Phase II trial of toremifene in androgen-independent prostate cancer: A penn cancer clinical trials group trial

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 24, Issue 3, 2001, Pages 283-285

  Stein, Steven ^a   Zoltick, Barbara ^a   Peacock, Thomas ^a   Holroyde, Christopher ^a   Haller, Daniel ^a   Armstead, Barbara ^a   Malkowicz, S Bruce ^a   Vaughn, David J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Prostate cancer; Toremifene

Indexed keywords

ANDROGEN; ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TOREMIFENE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPERGLYCEMIA; LIVER TOXICITY; MALE; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TOREMIFENE;

EID: 0034989461     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200106000-00015     Document Type: Article

References (16)

1. Cancer statistics, 2000
2. Studies on prostatic cancer. 1. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
3. A new triphenylate compound, Fc-1157a I. Hormonal effects
4. Toremifene, a new anti-estrogenic compound, for treatment of advanced breast cancer. Phase II study
5. Expression of the c-Ha-ras and neu oncogenes in DMBA-induced anti-estrogen treated rat mammary tumors
6. Mitotic activity, apoptosis, and TRPM-2 mRNA expression in DMBA-induced rat mammary carcinoma treated with the antiestrogen toremifene
7. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts
8. Phase I clinical and pharmacokinetics study of high dose toremifene in postmenopausal patients with advanced breast cancer
9. Prostate specific antigen decline after antiandrogen withdrawal
10. Bicalutamide for advanced prostate cancer: The natural versus treated history of disease
11. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal
12. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer
13. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized study with palliative end points
14. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer
15. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma
16. Phase II trial of toremifene for AIPC